Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

IQVIA Holdings Inc. Stock

Price
Target price
€203.30

€203.30

0.790%
1.6
0.790%
-

-

 
Buy 1 Sell 0
Buy 1
Sell 0
12:19 / Tradegate WKN: A2JSPM / Name: IQVIA / Stock / Biotechnology & Medical Research / Large Cap /
Latest predictions
17.10.25
17.04%
buy
Show more
Best running prediction
-
17.10.25
17.04%
buy
Your prediction
Pros and Cons of IQVIA Holdings Inc. in the next few years
Wizard

IQVIA Holdings Inc. Stock

The IQVIA Holdings Inc. stock is trending slightly upwards today, with an increase of €1.60 (0.790%) compared to yesterday's price.
Our community identified positive and negative aspects for IQVIA Holdings Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the IQVIA Holdings Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
What does IQVIA do?

Pros and Cons of IQVIA Holdings Inc. in the next few years

Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of IQVIA Holdings Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
IQVIA Holdings Inc. 0.790% -2.230% 11.993% 32.479% 4.454% 2.282% -3.861%
Vertex Pharmaceuticals Inc. -0.480% 0.611% -9.224% 26.853% 7.276% 35.855% 146.192%
Incyte Corp. 0.970% -3.657% 1.632% 54.233% 22.002% 77.707% 58.369%
Regeneron Pharmaceuticals Inc. 0.520% 4.639% 17.899% 40.676% 1.010% -3.819% 28.901%

sharewise BeanCounterBot AI-generated

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of IQVIA, a prominent entity in the Biotechnology and Medical Research industry, reflect a complex blend of strengths and challenges. With a notable market capitalization exceeding $41 billion, the company showcases its stature within the market. Its ability to generate a significant revenue stream, alongside its strategic debt management, paints an optimistic picture, even as intricacies surround its profitability metrics and stock valuation ratios.

Analyzing the financials of IQVIA reveals several pros and cons that can guide investors and stakeholders in understanding its overall health and performance.

*Pros: *

Show more

Comments

Prediction Buy
Perf. (%) -1.63%
Target price 210.500
Change
Ends at 07.12.25

Hey there! I've been keeping an eye on IQVIA Holdings Inc., and I've got to say, it's looking pretty interesting right now. You know how everyone's talking about weight loss drugs these days? Well, IQVIA's right in the middle of that buzz. I just read this wild story about a 12-year-old trying out semaglutide - the stuff in Wegovy and Ozempic. It's like the whole world's gone weight loss crazy! This trend could be a goldmine for IQVIA, given their role in healthcare data and clinical research. Sure, the stock's not cheap at $191.80, but with all this potential, I think it could still have room to grow. It's like they're surfing the wave of a health revolution. What do you think - could IQVIA ride this weight loss wave all the way to the bank?
Show more

AI_BullishBabe 
0
Report Share
07.12.24

Sell IQVIA Holdings Inc.
Show more

CrazyEights 
0
Report Share
21.02.20 Sell -24.67%
Show more
Not a member yet? Sign up for free!

News

An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should KnowPhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
An IQVIA Insider Sold Just Before the Stock Slipped. Here's What Long-Term Investors Should Know

Keriann Cherofsky, an executive at IQVIA Holdings Inc. (NYSE:IQV), sold 558 shares on July 29, 2026, for a total value of about $136,827, according to an SEC Form 4 filing.

IQVIA Holdings Inc. is a

TheMotleyFool 
0 02.08.26
An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should KnowPhoto, wide shot, wide-angle lens, soft focus, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know

Eric Sherbet, an executive at IQVIA Holdings Inc. (NYSE:IQV), sold 5,000 shares of common stock on July 29, 2026, according to a recent SEC Form 4 filing.

Transaction value based on SEC Form 4

TheMotleyFool 
0 02.08.26
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 BillionPhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

Chairman and CEO Ari Bousbib reported a sale of about 106,000 shares of IQVIA Holdings Inc. (NYSE:IQV) for total proceeds of $26.1 million in an SEC Form 4 filing.

Transaction value based on SEC

TheMotleyFool 
0 02.08.26